Last reviewed · How we verify
Menopur
At a glance
| Generic name | Menopur |
|---|---|
| Also known as | Menopur®, Menotropin, HP-hMG, highly purified menotrophin, gonadotropin |
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles (PHASE4)
- Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer. (PHASE3)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome (PHASE2)
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT (NA)
- Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Menopur CI brief — competitive landscape report
- Menopur updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI